Skip to main content
Log in

Endoglin/CD 105 may not be an optimal tumor endothelial treatment target

  • Letter to the editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Thorpe PE, Burrows FJ: Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 36: 237–231, 1995

    PubMed  Google Scholar 

  2. Griffioen AW, Damen C, Martinotti S, Blijham GH, Groenewegen G: Endothelial ICAM-1 expression is suppressed in human malignancies: role of angiogenic factors. Cancer Res, in press

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Griffioen, A.W., Damen, C.A., Blijham, G.H. et al. Endoglin/CD 105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res Tr 39, 239–240 (1996). https://doi.org/10.1007/BF01806191

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806191

Keywords

Navigation